Drugs & Therapy Perspectives

, Volume 21, Issue 1, pp 1–4 | Cite as

Letrozole is an effective option in the treatment of early-stage or advanced breast cancer in postmenopausal women

Drugs and Profile Reports

Letrozole, a highly specific, nonsteroidal third-generation aromatase inhibitor, is a potent inhibitor of estrogen synthesis that is of benefit to postmenopausal breast cancer patients. Extended adjuvant therapy with letrozole 2.5 mg/day improves disease-free survival in early breast cancer previously treated with tamoxifen; as neoadjuvant therapy, it is superior to tamoxifen. In advanced breast cancer, letrozole 2.5 mg/day is superior to tamoxifen 20 mg/day as first-line therapy, and as effective as anastrozole 1 mg/day and at least as effective as megestrol acetate 160 mg/day as second-line therapy. Letrozole is tolerated at least as well as tamoxifen, anastrozole or megestrol acetate.

Postmenopausal breast cancer common

In the western world, breast cancer is the most common cancer affecting women.[1] Approximately 80% of breast cancers occur in postmenopausal women, and they are the second leading cause of death in this group of women in the US.[2]

Endocrine therapy a mainstay



  1. 1.
    Beslija S, Bonneterre J, Burstein HJ, et al. Consensus on medical treatment of metastatic breast cancer. Breast Cancer Res Treat 2003; 81 Suppl. 1: S1–7CrossRefGoogle Scholar
  2. 2.
    Simon MS, Ibrahim D, Newman L, et al. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging 2002; 19(6): 453–63PubMedCrossRefGoogle Scholar
  3. 3.
    Come SE, Buzdar AU, Arteaga CL, et al. Second international conference on recent advances and future directions in endocrine manipulation of breast cancer: summary consensus statement. Clin Cancer Res 2003 Jan; 9 Suppl. : 443s–6sPubMedGoogle Scholar
  4. 4.
    Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 2004; 64(11): 1213–30PubMedCrossRefGoogle Scholar
  5. 5.
    Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349(19): 1793–802PubMedCrossRefGoogle Scholar
  6. 6.
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001 Nov; 12(11): 1527–32PubMedCrossRefGoogle Scholar
  7. 7.
    Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003 Jun 1; 21(11): 2101–9PubMedCrossRefGoogle Scholar
  8. 8.
    Mouridsen H, Sun Y, Gershanovich M, et al. Significantly longer time to progression for Femara (letrozole) in patients with or without prior adjuvant tamoxifen: updated analysis of the double-blind, randomized, multinational phase III trial of letrozole compared to tamoxifen as first-line hormonal therapy for advanced breast cancer [abstract no. 256]. 25th Annual San Antonio Breast Cancer Symposium; 2002 Dec 11–14; San AntonioGoogle Scholar
  9. 9.
    Smith IE. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 2003 Sep; 86(3-5): 289–93PubMedCrossRefGoogle Scholar
  10. 10.
    Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001 M 15; 19(14): 3357–66PubMedGoogle Scholar
  11. 11.
    Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453–61PubMedGoogle Scholar
  12. 12.
    Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003 Nov; 39(16): 2318–27PubMedCrossRefGoogle Scholar
  13. 13.
    Novartis Oncology. About Femara: European summary of product characteristics [online]. Available from URL: [Accessed 2004 Sep 2]
  14. 14.
    Novartis Oncology. Femara prescribing information [online]. Available from URL: [Accessed 2004 Sep 2]

Copyright information

© Adis Data Information BV 2005

Personalised recommendations